Morphine or Fentanyl for Refractory dyspnea in COPD - MoreFoRCOPD

niversity Medical Center Groningen0 个研究点目标入组 60 人开始时间: 2018年11月19日最近更新: 2019年6月30日

适应症

试验速览

暂无简介。

•COPD GOLD class III or IV, according to GOLD criteria.
•- Post-bronchodilatation FEV1/FVC < 70% and FEV1 < 50% pred.
•Complaints of refractory dyspnea as established by patient and doctor.
•mMRC score = 3.
•Life expectancy of = 2 months.
•Optimized standard therapy according to Dutch LAN guideline for diagnosis and treatment of COPD.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 30
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 30

•Other severe disease with chronic pain or chronic dyspnea (a non-susbstantial component of left sided heart failure is acceptable).
•Current use of opioids for whatever indication
•Allergy / intolerance for opioids
•Psychiatric disease, not related to severe COPD.
•Exacerbation of COPD eight weeks prior to inclusion or between screening and randomization.
•Problematic (leading to medical help or social problems) substance abuse during the last five years.
•Active malignancy, with the exception of planocellular or basal cell carcinoma of the skin.
•eGFR <15 ml/min

发起方